Overview

SUBLOCADE Rapid Initiation Extension Study

Status:
Completed

Trial end date:
2020-05-15

Target enrollment:

Participant gender:

Summary

A single center, open-label SUBLOCADE treatment extension study in which up to 25 participants diagnosed with moderate to severe opioid use disorder (OUD) could be enrolled.

Phase:

Phase 4

Details

Lead Sponsor:

Indivior Inc.

Treatments:

Buprenorphine